Table 1.

Characteristics of the study population with CIMP-positive¹ cancers

	Weighted N2	Prevalence (%)
Age
<50	52	6.6
51–69	406	51.6
≥ 70	329	41.8
Sex
Male	322	41.0
Female	464	59.0
Tumor Site3
Proximal	636	80.9
Distal	83	10.5
Rectal	68	8.6
MSI status4
MSS	280	35.6
MSI-L	81	10.3
MSI-H	424	53.9
Missing	2	0.25
BRAF mutation
Present5	490	62.3
Absent	274	34.8
Missing	22	2.9
KRAS mutation
Present6	138	17.6
Absent	520	66.2
Missing	128	16.3
Family History7
No	632	80.3
Yes	149	18.9
Missing	6	0.76
N methylated:
CACNA1G	619	78.7
IGF2	737	93.8
NEUROG1	781	99.4
RUNX3	693	88.2
SOCS1	429	54.6
MLH1	402	51.2

¹Defined as a PMR ≥10 for at least 3 of 5 genes: CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1.

²As defined in the text the sampling weights are the inverse of the sampling fraction which corrected for the oversampling of case probands by age, race and family history. N’s are rounded to the nearest whole number.

³Tumors were labeled as ascending colon if located in the cecum through the splenic flexure. Tumors were labeled as distal colon if located in the descending colon through the sigmoid colon and included tumors ‘overlapping the colon and rectum.’ Tumors were labeled as rectal if located in the rectum or rectosigmoid junction.

⁴MSI status was determined using 10 microsatellites as described in the text.

⁵Presence of the BRAF V600E mutation.

⁶Presence of either a codon 12 or codon 13 KRAS mutation.

⁷Defined as a Self-reported history of CRC in at least one 1^st degree relative.